加速全球化布局：英硅智能联手康哲药业、信达生物88.5亿美元出海、复方丹参滴丸美国梦碎_老虎社区_美港股上老虎

加速全球化布局：英硅智能联手康哲药业、信达生物88.5亿美元出海、复方丹参滴丸美国梦碎

中国粉体网02-10

中国粉体网讯1、英硅智能：与康哲药业达成药物研发战略合作2月10日英硅智能发布公告，其已与康哲药业达成药物研发战略合作。双方聚焦中枢神经系统及自身免疫疾病领域，将开展一系列由AI赋能的创新药物研发合作。合作将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，共同推进不少于2个研发项目开发。2、诺诚健华宣布ICP-538成为中国首款获批临床的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2610487645?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-10 17:29","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2610487645","market":"hk","top_or_hot":-1,"title":"加速全球化布局：英硅智能联手康哲药业、信达生物88.5亿美元出海、复方丹参滴丸美国梦碎","media":"中国粉体网","content":"<div>\n<p>中国粉体网讯1、英硅智能：与康哲药业达成药物研发战略合作2月10日英硅智能发布公告，其已与康哲药业达成药物研发战略合作。双方聚焦中枢神经系统及自身免疫疾病领域，将开展一系列由AI赋能的创新药物研发合作。合作将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，共同推进不少于2个研发项目开发。2、诺诚健华宣布ICP-538成为中国首款获批临床的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210172925a492f653&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>加速全球化布局：英硅智能联手康哲药业、信达生物88.5亿美元出海、复方丹参滴丸美国梦碎</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n加速全球化布局：英硅智能联手康哲药业、信达生物88.5亿美元出海、复方丹参滴丸美国梦碎\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-10 17:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210172925a492f653&s=b><strong>中国粉体网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中国粉体网讯1、英硅智能：与康哲药业达成药物研发战略合作2月10日英硅智能发布公告，其已与康哲药业达成药物研发战略合作。双方聚焦中枢神经系统及自身免疫疾病领域，将开展一系列由AI赋能的创新药物研发合作。合作将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，共同推进不少于2个研发项目开发。2、诺诚健华宣布ICP-538成为中国首款获批临床的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210172925a492f653&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2328871848.SGD","symbol_name":"Eastspring Investments - China A Shares Growth AS SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210172925a492f653&s=b","article_id":"2610487645","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210172925a492f653&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610487645","pubTimestamp":1770715757,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"中国粉体网讯1、英硅智能：与康哲药业达成药物研发战略合作2月10日英硅智能发布公告，其已与康哲药业达成药物研发战略合作。这是中国首款、全球第二款进入临床的VAV1分子胶降解剂。根据协议条款，公司将获得3.5亿美元首付款；在达成后续特定里程碑事件后，还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","BK1191":"制药","BK1161":"生物科技","BK1593":"医美概念股","03696":"英矽智能","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","01801":"信达生物","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","00867":"康哲药业","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","BK1583":"高瓴概念","SG9999015978.USD":"利安颠覆性创新基金A","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","BK1589":"北水核心资产","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","BK1141":"生命科学工具和服务"},"translate_title":"Accelerating the layout of globalization: Yingsi Intelligent joins forces with CMS and Cinda Biologics to go overseas for US $8.85 billion, and the American dream of compound Danshen dripping pills is broken","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1.5,"00867":1.5,"03696":0.9},"content_text":"中国粉体网讯1、英硅智能：与康哲药业达成药物研发战略合作2月10日英硅智能发布公告，其已与康哲药业达成药物研发战略合作。双方聚焦中枢神经系统及自身免疫疾病领域，将开展一系列由AI赋能的创新药物研发合作。合作将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，共同推进不少于2个研发项目开发。2、诺诚健华宣布ICP-538成为中国首款获批临床的VAV1分子胶降解剂2月9日，诺诚健华宣布，公司自主研发的VAV1分子胶降解剂ICP-538获国家药品监督管理局（NMPA）药品审评中心（CDE）批准开展临床研究。这是中国首款、全球第二款进入临床的VAV1分子胶降解剂。3、众生药业：子公司一类创新药昂拉地韦项目两项III期临床试验获积极结果2月8日，众生药业控股子公司众生睿创的昂拉地韦颗粒治疗2~11岁单纯性甲型流感患者的III期临床试验、昂拉地韦片治疗12~17岁青少年单纯性甲型流感患者的III期临床试验，于近日获得顶线分析数据。初步结果表明，昂拉地韦颗粒在2~11岁单纯性甲型流感参与者、昂拉地韦片在12~17岁单纯性甲型流感参与者中疗效积极、安全性良好。4、88.5亿美元！千亿创新药巨头又有大动作2月8日，信达生物公告，公司与礼来制药达成战略合作，推进肿瘤及免疫领域创新药物的全球研发进程。根据协议条款，公司将获得3.5亿美元首付款；在达成后续特定里程碑事件后，还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。此外，公司有权就各产品在大中华区以外的净销售额获得梯度的销售分成。5、中成药欧美国家上市有多难？复方丹参滴丸出海合作终止，在美临床试验近30年未获批2月6日晚，天士力公告，与美国Arbor公司终止复方丹参滴丸（T89）出海合作，收回美国独家销售等权益，已收相关款项750万美元。T89是天士力中药国际化核心产品，1998年通过美国FDA临床用药申请，2016年完成Ⅲ期临床试验，成为首个达成该阶段的复方中药制剂，但至今未获FDA批准上市。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}